{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:53:06Z","timestamp":1760100786260,"version":"3.37.3"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Scaife Family Foundation"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.ygyno.2015.06.026","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T05:54:55Z","timestamp":1435038895000},"page":"548-553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer"],"prefix":"10.1016","volume":"138","author":[{"given":"Sarah E.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruosha","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S.","family":"Petschauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"O'Neal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda W.","family":"Keeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin K.","family":"Zorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2015.06.026_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin."},{"issue":"3 Pt 2","key":"10.1016\/j.ygyno.2015.06.026_bb0010","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1006\/gyno.1994.1347","article-title":"Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials","volume":"55","author":"Thigpen","year":"1994","journal-title":"Gynecol. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2015.06.026_bb0015","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2015.06.026_bb0020","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2015.06.026_bb0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"first-page":"10016","year":"2004","series-title":"Oxaliplatin package insert","key":"10.1016\/j.ygyno.2015.06.026_bb0030"},{"issue":"14","key":"10.1016\/j.ygyno.2015.06.026_bb0035","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1200\/JCO.2003.11.015","article-title":"Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study","volume":"21","author":"Takimoto","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2015.06.026_bb0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ygyno.2014.04.039","article-title":"Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity","volume":"134","author":"Taylor","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.026_bb0045","first-page":"5896","article-title":"Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics","volume":"9","author":"Morgan","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.06.026_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0731-7085(00)00377-0","article-title":"Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin","volume":"24","author":"Morrison","year":"2000","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ygyno.2015.06.026_bb0055","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00280-002-0531-6","article-title":"Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat","volume":"50","author":"Liu","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"Suppl.1","key":"10.1016\/j.ygyno.2015.06.026_bb0060","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1525-1438.2007.01099.x","article-title":"Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer","volume":"18","author":"Howell","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2015.06.026_bb0065","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer: the M. D. Anderson Symptom Inventory","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2015.06.026_bb0070","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jpainsymman.2007.04.017","article-title":"Evaluation of the Symptom Representation Questionnaire (SRQ) for assessing cancer-related symptoms","volume":"35","author":"Donovan","year":"2008","journal-title":"J. Pain Symptom Manag."},{"issue":"15","key":"10.1016\/j.ygyno.2015.06.026_bb0075","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1200\/JCO.2003.03.077","article-title":"Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a Gynecologic Group Study","volume":"21","author":"Fracasso","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2015.06.026_bb0080","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/oxfordjournals.annonc.a010500","article-title":"Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer","volume":"7","author":"Chollet","year":"1996","journal-title":"Ann. Oncol."},{"issue":"1B","key":"10.1016\/j.ygyno.2015.06.026_bb0085","first-page":"495","article-title":"Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)","volume":"28","author":"Kalykaki","year":"2008","journal-title":"Anticancer Res."},{"issue":"8","key":"10.1016\/j.ygyno.2015.06.026_bb0090","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/IGC.0b013e3181b62f38","article-title":"Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer","volume":"19","author":"Seliger","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2015.06.026_bb0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00404-008-0592-9","article-title":"Oxaliplatin\/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma","volume":"278","author":"Rosa","year":"2008","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2015.06.026_bb0100","first-page":"13","article-title":"Pharmacokinetics and safety profile of oxaliplatin","volume":"25","author":"Extra","year":"1998","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2015.06.026_bb0105","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.2000.18.6.1193","article-title":"Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group","volume":"18","author":"Piccart","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2015.06.026_bb0110","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ejca.2011.02.012","article-title":"Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours","volume":"47","author":"de Jonge","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.06.026_bb0115","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2015.06.026_bb0120","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2015.06.026_bb0125","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1586\/14737140.1.1.142","article-title":"Intraperitoneal chemotherapy in the management of malignant disease","volume":"1","author":"Markman","year":"2001","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"13","key":"10.1016\/j.ygyno.2015.06.026_bb0130","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815300470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815300470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T13:35:13Z","timestamp":1620826513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815300470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0090825815300470"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.06.026","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}